Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study: ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach).

Trial Profile

A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study: ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin; Epirubicin
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CRITICS
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 09 Apr 2018 Primary endpoint (Over all Survival) has not been met, according to results published in the Lancet Oncology.
    • 09 Apr 2018 Between Jan 11, 2007, and April 17, 2015, we enrolled 788 patients and randomly assigned them to receive postoperative chemotherapy (n=393) or postoperative chemoradiotherapy (n=395), according to results published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top